BioSpace News Archive

Company focused on broadening access to innovative solutions for people with type 1 and type 2 diabetes and designing high-touch customer care experiences

AbbVie, a research-based global biopharmaceutical company, is investing $50 million in a five-year program to support underserved Black communities across the United States . AbbVie will collaborate with six nonprofit partners, including Direct Relief , University of Chicago Medicine’s Urban Health Initiative , Na

Stand Up for Accurate Prenatal Answers, a nonprofit working to ensure that all women in the United States receive access to the most accurate non-invasive prenatal testing (NIPT) options, today applauded a recent decision by Aetna to begin providing permanent unrestricted NIPT coverage to all expectant women.

Hyland Healthcare to implement complete imaging solution to better manage unstructured patient content

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has received the Advocacy/Policy Award from the Reagan-Udall Foundation for the Food and Drug Administration. MJFF is the second organization ever to receive this award, which honors individuals or groups that have made an impact to improve public health through advocacy and p

As the resurgence of COVID-19 activity continues in Canada, we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians and public health, laboratory and healthcare capacity.

Bayer Radiology is announcing Radimetrics ® v3.0, the newest evolution of its enterprise dose management application. The newly designed system supports many of the latest accreditation standards on dose reporting and tracking, protoco

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced it submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1/2 clinical trial of EDIT-301, an experimental CRISPR/Cas12a gene editing medicine in development for the treatment of sickle cell disease

AngioDynamics, Inc., a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, announced that it will report financial results for the second quarter of fiscal year 2021 before the market open on Thursday, January 7, 2021.

LAIR1, through interactions with tumor-associated collagens, may form a stromal checkpoint that imposes signaling-based immune suppression and impedes anti-tumor immunity